

ONE HUNDRED FOURTEENTH CONGRESS
Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

July 21, 2015

Dr. Jeffrey W. Chell
Chief Executive Officer
National Marrow Donor Program
3001 Broadway Street, N.E.
Minneapolis, MN 55413

Dear Dr. Chell:


Thank you for appearing before the Subcommittee on Health on June 25, 2015, to testify at the hearing entitled "Examining Public Health Legislation: H.R. 2820, H.R. 1344, and H.R. 1462."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on August 4, 2015. Your responses should be mailed to Graham Pittman, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to graham.pittman@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,


Joseph R. Pitts
Chairman
Subcommittee on Health

cc: The Honorable Gene Green, Ranking Member, Subcommittee on Health

Attachment

Attachment — Additional Questions for the Record

The Honorable Representative Matsui

1. You mentioned in your testimony some of the roles that the National Marrow Donor Program plays in addition to running the national registry. Can you elaborate a bit on all the work that Be The Match/NMDP does?
2. Can you elaborate on the way that Be the Match coordinates internationally and the difference that makes for the possibility of a patient finding a match?
3. What about research – how has data collection through the registry and other activities led to improved patient outcomes?
4. You mentioned that current pediatric research focuses not only on malignancies, but also on non-cancer diseases that can still be fatal if untreated, like sickle cell disease. How does Be The Match/NMDP help children with both cancer and non-cancerous diseases?
5. As you mentioned, the number of transplants for racial and ethnic minority patients has increased substantially from the year 2000 to today. What efforts is Be The Match making to continue to expand the diversity of the registry to ensure that minority patients can find matches?